Achieve Life Sciences (NASDAQ:ACHV) Posts Earnings Results, Misses Expectations By $0.64 EPS

Achieve Life Sciences (NASDAQ:ACHV) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.64), FiscalAI reports.

Achieve Life Sciences Price Performance

NASDAQ ACHV opened at $6.69 on Thursday. The company has a market cap of $686.80 million, a PE ratio of -4.32 and a beta of 2.24. The firm’s 50 day moving average price is $6.03 and its 200-day moving average price is $4.90. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.62 and a current ratio of 2.62. Achieve Life Sciences has a 52-week low of $2.45 and a 52-week high of $7.11.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ACHV. UBS Group reissued a “buy” rating on shares of Achieve Life Sciences in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Wednesday. Canaccord Genuity Group set a $13.00 price target on Achieve Life Sciences and gave the company a “buy” rating in a report on Monday, April 20th. Raymond James Financial reissued a “strong-buy” rating and issued a $18.00 price objective on shares of Achieve Life Sciences in a research note on Wednesday. Finally, Wall Street Zen upgraded Achieve Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Achieve Life Sciences has an average rating of “Buy” and a consensus price target of $15.00.

Institutional Trading of Achieve Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC purchased a new position in shares of Achieve Life Sciences in the 1st quarter valued at $32,000. Magnolia Capital Advisors LLC purchased a new stake in shares of Achieve Life Sciences during the 4th quarter worth $64,000. HRT Financial LP bought a new stake in Achieve Life Sciences during the fourth quarter valued at about $93,000. Charles Schwab Investment Management Inc. bought a new stake in Achieve Life Sciences during the fourth quarter valued at about $99,000. Finally, Jump Financial LLC purchased a new stake in shares of Achieve Life Sciences during the fourth quarter valued at about $104,000. Institutional investors own 33.52% of the company’s stock.

Key Headlines Impacting Achieve Life Sciences

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $12.00 price target for Achieve Life Sciences. The firm modestly improved its Q3 2026 EPS estimate to a loss of $0.22 from $0.23 and its Q4 estimate to a loss of $0.26 from $0.30, suggesting somewhat better near-term expectations. MarketBeat Achieve Life Sciences analyst estimates
• Positive Sentiment: The analyst expects Achieve Life Sciences to move toward profitability in future years, forecasting positive EPS of $0.23 in 2028, $0.97 in 2029 and $1.47 in 2030. That long-term outlook may support the stock’s valuation if the company successfully commercializes its treatment candidate. Achieve Life Sciences stock profitability article
• Neutral Sentiment: HC Wainwright’s revised estimates imply that the timing of profitability remains uncertain: FY2027 projected losses improved slightly to $0.79 per share, while estimates for 2028–2030 profit were reduced modestly. The firm nevertheless retained its Buy rating and $12 target.
• Negative Sentiment: Achieve Life Sciences reported a second-quarter 2026 loss of $0.80 per share, far worse than the consensus loss of $0.16. The disappointing result highlights ongoing operating losses and likely contributed to the stock’s decline. Achieve Life Sciences second-quarter 2026 results
• Negative Sentiment: HC Wainwright sharply lowered its FY2026 EPS forecast to a loss of $1.54 from a loss of $0.92, materially below the current consensus loss estimate of $0.81. This downward revision indicates greater expected spending or losses in the near term and offsets the improved quarterly estimates.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.